Marina Biotech, Inc. (OTC: MRNA), a leading nucleic acid-based drug discovery and development company, announced today that it has entered into a licensing agreement with Tekmira Pharmaceuticals Corporation with respect to a worldwide, non-exclusive license to Marina Biotech’s unlocked nucleobase analog technology for the development of RNA interference therapeutics.  

Pryor Cashman Partners Stephen Goodman and Jeffrey Johnson, along with Counsel Michael Campoli, represented Marina Biotech in the transaction.